Fresenius Medical (FMS) is a “Dependable Top-Line Grower”, Says Fiduciary Management
Fiduciary Management Inc., an investment management firm, published its “International Equity” first quarter 2021 investor letter – a copy of which can be downloaded here. A return of 7.2% (currency hedged) was reported by the FMI International portfolios for the Q1 of 2021, compared to its MSCI EAFE benchmark that delivered a 7.59% return in local currency (LOC) and 3.48% in U.S. Dollars (USD) over the same period. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021.
Fiduciary Management, in their Q1 2021 investor letter, mentioned Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) and shared their insights on the company. Fresenius Medical Care AG & Co. KGaA Limited is a Bad Homburg, Germany-based kidney dialysis centers company that currently has a $22.2 billion market capitalization. Since the beginning of the year, FMS delivered a -8.76% return, while its 12-month gains are up 8.16%. As of April 15, 2021, the stock closed at $37.92 per share.